| Driver mutations in histone H3. 3 and chromatin remodelling genes in paediatric glioblastoma J Schwartzentruber, A Korshunov, XY Liu, DTW Jones, E Pfaff, K Jacob, ... Nature 482 (7384), 226-231, 2012 | 2199 | 2012 |
| Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma D Sturm, H Witt, V Hovestadt, DA Khuong-Quang, DTW Jones, ... Cancer cell 22 (4), 425-437, 2012 | 1629 | 2012 |
| Medulloblastoma comprises four distinct molecular variants PA Northcott, A Korshunov, H Witt, T Hielscher, CG Eberhart, S Mack, ... Journal of clinical oncology 29 (11), 1408, 2011 | 1326 | 2011 |
| Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma H Witt, SC Mack, M Ryzhova, S Bender, M Sill, R Isserlin, A Benner, ... Cancer cell 20 (2), 143-157, 2011 | 483 | 2011 |
| DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis F Sahm, D Schrimpf, D Stichel, DTW Jones, T Hielscher, S Schefzyk, ... The lancet oncology 18 (5), 682-694, 2017 | 465 | 2017 |
| Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ... Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012 | 415 | 2012 |
| Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma J Hillengass, K Fechtner, MA Weber, T Bauerle, S Ayyaz, C Heiss, ... J Clin Oncol 28 (9), 1606-1610, 2010 | 401 | 2010 |
| The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation G Leprivier, M Remke, B Rotblat, A Dubuc, ARF Mateo, M Kool, ... Cell 153 (5), 1064-1079, 2013 | 372 | 2013 |
| Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer A Ward, A Balwierz, JD Zhang, M Küblbeck, Y Pawitan, T Hielscher, ... Oncogene 32 (9), 1173-1182, 2013 | 297 | 2013 |
| Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis EM Thompson, T Hielscher, E Bouffet, M Remke, B Luu, S Gururangan, ... The lancet oncology 17 (4), 484-495, 2016 | 252 | 2016 |
| TERT promoter mutations and risk of recurrence in meningioma F Sahm, D Schrimpf, A Olar, C Koelsche, D Reuss, J Bissel, A Kratz, ... JNCI: Journal of the National Cancer Institute 108 (5), 2016 | 251 | 2016 |
| Adult medulloblastoma comprises three major molecular variants M Remke, T Hielscher, PA Northcott, H Witt, M Ryzhova, A Wittmann, ... Journal of clinical oncology 29 (19), 2717-2723, 2011 | 249 | 2011 |
| Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct PA Northcott, T Hielscher, A Dubuc, S Mack, D Shih, M Remke, ... Acta neuropathologica 122 (2), 231-240, 2011 | 233 | 2011 |
| Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del (17p), t (4; 14), gain 1q, hyperdiploidy, and tumor load K Neben, A Jauch, T Hielscher, J Hillengass, N Lehners, A Seckinger, ... Journal of clinical oncology 31 (34), 4325-4332, 2013 | 219 | 2013 |
| Molecular staging of intracranial ependymoma in children and adults A Korshunov, H Witt, T Hielscher, A Benner, M Remke, M Ryzhova, ... Journal of Clinical Oncology 28 (19), 3182-3190, 2010 | 217 | 2010 |
| Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma D Hose, T Rème, T Hielscher, J Moreaux, T Messner, A Seckinger, ... Haematologica 96 (1), 87, 2011 | 208 | 2011 |
| Cell competition is a tumour suppressor mechanism in the thymus VC Martins, K Busch, D Juraeva, C Blum, C Ludwig, V Rasche, ... Nature 509 (7501), 465-470, 2014 | 205 | 2014 |
| Combining information regarding chromosomal aberrations t (4; 14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients … K Neben, A Jauch, U Bertsch, C Heiss, T Hielscher, A Seckinger, T Mors, ... Haematologica 95 (7), 1150, 2010 | 194 | 2010 |
| FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma M Remke, T Hielscher, A Korshunov, PA Northcott, S Bender, M Kool, ... J Clin Oncol 29 (29), 3852-3861, 2011 | 172 | 2011 |
| Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma EK Mai, U Bertsch, J Dürig, C Kunz, M Haenel, IW Blau, M Munder, ... Leukemia 29 (8), 1721-1729, 2015 | 171 | 2015 |
